Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Jazz Pharmaceuticals plc - Ordinary Shares (NQ:JAZZ)

100.34 -2.44 (-2.37%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Jazz Pharmaceuticals plc - Ordinary Shares

< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
Jazz Pharmaceuticals Announces Q3 2022 Financial Results, Raises Total Revenue Guidance
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) announced its financial results late Wednesday for the third quarter of 2022 and raised the mid-point of 2022 total revenue guidance. 
Via Benzinga
Why Axsome Therapeutics Stock Slipped Today
Investors traded out of the company following the latest earnings release, but only to a modest degree. 
Via The Motley Fool
3 Top Healthcare Stocks to Buy for November
Catalysts lie ahead for these promising stocks. 
Via The Motley Fool
Why Shares of Zymeworks Rose 12.18% on Monday
The biotech stock's shares may have been pushed by a short squeeze. 
Via The Motley Fool
2 Marijuana Stocks That Are Set for a Comeback
Don't overlook these top stocks when investing in the marijuana space. 
Via The Motley Fool
Jazz Pharma's Zepzelca For Lung Cancer Flunked Confirmatory Trial, But FDA Will Not Pull Accelerated Approval
A petition was filed requesting that the FDA initiate proceedings to withdraw approval of all medications containing lurbinectedin, currently marketed under the brand Zepzelca by Jazz Pharmaceuticals... 
Via Benzinga
Why Zymeworks Stock Is Soaring Today
Investors applauded a major licensing deal with Jazz Pharmaceuticals. 
Via The Motley Fool
Jazz Pharmaceuticals' Return On Capital Employed Insights
  
Via Benzinga
Analyst Moves To Sidelines After Jazz Pharma Deal Shifts Zymeworks To Early Stage Pipeline
Via Benzinga
Why Is Zymeworks (ZYME) Stock Up Today?
Zymeworks (ZYME) stock is climbing higher on Wednesday after the company signed a licensing agreement with Jazz Pharmaceuticals (JAZZ). 
Via InvestorPlace
Jazz Obtains Exclusive Rights To Zymeworks' Cancer Candidate In Almost $2B Biobuck Deal
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
2 Biotech Stocks You Can Buy and Hold for the Next Decade
These two durable companies can navigate the market downturn and beyond. 
Via The Motley Fool
'Street Underestimates Jazz Pharma's Cash-Flow' Says This Analyst
Via Benzinga
Where Jazz Pharmaceuticals Stands With Analysts
Within the last quarter, Jazz Pharmaceuticals (NASDAQ:JAZZ) has observed the following analyst ratings: 
Via Benzinga
3 Red-Hot Stocks That Could Continue to Beat the Market
Investors are betting on these companies' revenue growth prospects. 
Via The Motley Fool
3 Top Marijuana Stocks to Buy for the Long Haul
The three have the financial strength to benefit from increased cannabis sales and cannabis therapies. 
Via The Motley Fool
3 Stocks Savvy Investors Are Buying Hand Over Fist
These high-flying stocks are defying the bear market. 
Via The Motley Fool
Japan Is Inching Toward Cannabis Legalization, Companies Like This One Could Benefit
A Japanese health ministry panel recommended that marijuana-derived medicines be treated the same as pharmaceuticals, reported Bloomberg. The expert panel, convened on Thursday, recommended a revision... 
Via Benzinga
UBS Slashes PT On This Stock By Over 89%? Plus Evercore ISI Group Predicts $150 For First Solar
Evercore ISI Group boosted First Solar, Inc. (NASDAQ: FSLR) price target from $88 to $150. First Solar shares rose 1.7% to $138.49 in pre-market trading. 
Via Benzinga
5 Analysts Have This to Say About Jazz Pharmaceuticals
Jazz Pharmaceuticals (NASDAQ:JAZZ) has observed the following analyst ratings within the last quarter: 
Via Benzinga
7 Top-Rated Biotech Stocks to Buy for Q4
A new White House program makes these seven names some outstanding biotech stocks to buy for the fourth quarter. 
Via InvestorPlace
The Bright Future Of Cannabis Isn’t In Dispensaries - It’s In The Biotech Lab
Cannabis businesses offer a lucrative opportunity for investors, but one sector in particular represents untapped potential: cannabinoid pharmaceuticals. 
Via Talk Markets
Recap Of Thursday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
Jazz' Epidiolex, The Only FDA-Approved CBD Drug, Enters Phase 3 Trial Evaluating Its Effects In Patients With Myoclonic-Atonic Seizures
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) has initiated a new Phase 3 trial to investigate the efficacy and safety of Epidiolex (cannabidiol), known as Epidyolex in Europe, in children and adolescents... 
Via Benzinga
Biotech Daily: Merck's Two Combo Cancer Trials Miss Main Goal, Approval For Sinovac's COVID-19 Shot For Youngest Kids, Alnylam Aces Protein Disorder Trial
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
7 Biotech Stocks to Buy for Q3
These biotech stocks could be good buys due for a few reasons, including great R&D pipelines and treatments with promising market potential. 
Via InvestorPlace
Aurinia Pharmaceuticals Skids With Its Buyout Thesis Hanging By A Thread
The company just hired three new executives, likely putting a buyout in the rearview. 
Via Investor's Business Daily
Cannabis Stocks Struggle Through Q2 2022
An overview of how cannabis stocks fared in Q2 and what investors should understand about the space. 
Via Talk Markets
Needham Previews Neurocrine's Upcoming Mid-Stage Data from Essential Tremor Study
Needham previews the upcoming Phase 2 data readout for Neurocrine Biosciences Inc's (NASDAQ: NBIX) NBI-827104, a t-type calcium channel blocker in essential tremor (ET), by mid-2022. 
Via Benzinga
< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.